CN Patent
CN101155804A — 用于治疗精神疾病的哌嗪取代的苯并噻吩
Assigned to Otsuka Pharmaceutical Co Ltd · Expires 2008-04-02 · 18y expired
What this patent protects
本发明提供一种由通式(1)表示的杂环化合物:本发明的化合物对于包括中枢神经系统疾病在内的精神疾病具有广泛的治疗谱,无副作用且具有很高的安全性。
USPTO Abstract
本发明提供一种由通式(1)表示的杂环化合物:本发明的化合物对于包括中枢神经系统疾病在内的精神疾病具有广泛的治疗谱,无副作用且具有很高的安全性。
Drugs covered by this patent
- Rexulti (BREXPIPRAZOLE) · Otsuka
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.